[an error occurred while processing this directive]

Research progress in heritable dyslipidemia

Expand
  • 1. Attardi Institute of Mitochondrial Biomedicine, Wenzhou Medical College, Wenzhou 325035, China; 
    2. Zhejiang Provincial Key Laboratory of Medical Genetics, Wenzhou Medical College, Wenzhou 325035, China; 
    3. Emergercy Medical Department, the First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China; 
    4. College of Life Sciences, Zhejiang University, Hangzhou 310058, China

Received date: 2013-03-24

  Revised date: 2013-05-16

  Online published: 2013-10-25

Abstract

Dyslipidemia is defined as high levels of serum cholesterol and/or triglycerides. Dyslipidemia often leads to severe cardiovascular diseases including coronary heart disease and stroke as the first clinical manifestation, thus threatening the health of human beings. Dyslipidemia diseases can be caused by the genetic factors, including the Mandelian or polygenic inheritance. Traditional methods of identifying genes associated with dyslipidemia are mainly DNA sequencing and linkage analysis, suitable for Mendelian genetic dyslipidemia disease. The rise of next-generation sequencing technology applies to not only Mandelian inheritance, but also complex forms of dyslipidemia diseases. Since 2006, genome-wide association studies (GWAS) screened out many causative genes associated with dyslipidemia, and most of these genes were the previously identified ones by the pedigree-based classic approaches. Furthermore, GWAS revealed that there were the different frequencies of gene variations related to complex forms of dyslipidemia diseases. Most of the identified single nucleotide polymorphisms (SNPs) associated with dyslipidemia are located in non-coding regions and thus people gradually focus on the gene variations of these loci. The identification of the causative genes will provide new insights into the pathophysiology of dyslipidemia diseases and a step toward therapeutic intervention. This review summarized recent pro-gress in heritable dyslipidemia.

Cite this article

HE Yi-Qun, XU Mei-Fen, YU Han, GENG Jun-Wei, SHI Su-Xue, XUE Ling, LU Zhong-Qiu, GUAN Min-Xin . Research progress in heritable dyslipidemia[J]. Hereditas(Beijing), 2013 , 35(11) : 1237 -1243 . DOI: 10.3724/SP.J.1005.2013.01237

References

[1] Lehrman MA, Schneider WJ, Südhof TC, Brown MS, Goldstein JL, Russell DW. Mutation in LDL receptor: Alu- Alu recombination deletes exons encoding transmembrane and cytoplasmic domains. Science, 1985, 227(4683): 140–146.

[2] 唐新, 林婴, 刘兵, 马誓, 杨洋, 杨正林. 家族性高甘油三酯血症家系的候选基因位点连锁分析. 中华医学遗传学杂志, 2009, 26(5): 499–503.

[3] Garcia CK, Wilund K, Arca M, Zuliani G, Fellin R, Maioli M, Calandra S, Bertolini S, Cossu F, Grishin N, Barnes R, Cohen JC, Hobbs HH. Autosomal recessive hypercholes-terolemia caused by mutations in a putative LDL receptor adaptor protein. Science, 2001, 292(5520): 1394–8.

[4] Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derré A, Villéger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet, 2003, 34(2): 154–156.

[5] Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science, 1986, 232(4746): 34–47.

[6] Soria LF, Ludwig EH, Clarke HR, Vega GL, Grundy SM, McCarthy BJ. Association between a specific apolipopro-tein B mutation and familial defective apolipoprotein B-100. Proc. Proc Natl Acad Sci USA, 1989, 86(2): 587– 591.

[7] Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Se-quence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med, 2006, 354(12): 1264–1272.

[8] Kryukov GV, Pennacchio LA, Sunyaev SR. Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. Am J Hum Genet, 2007, 80(4): 727–739.

[9] Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, Cooper DN. The Human Gene Mutation Da-tabase: 2008 update. Genome Med, 2009, 1(1): 13.

[10] Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, Dent KM, Huff CD, Shannon PT, Jabs EW, Nickerson DA, Shendure J, Bamshad MJ. Exome sequencing identifies the cause of a mendelian disorder. Nat Genet, 2010, 42(1): 30–35.

[11] Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, Garimella KV, Fisher S, Abreu J, Barry AJ, Fennell T, Banks E, Ambrogio L, Cibulskis K, Kernytsky A, Gonzalez E, Rudzicz N, Engert JC, DePristo MA, Daly MJ, Cohen JC, Hobbs HH, Altshuler D, Schonfeld G, Ga-briel SB, Yue P, Kathiresan S. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipide-mia. N Engl J Med, 2010, 363(23): 2220–2227.

[12] Burnett JR, Shan J, Miskie BA, Whitfield AJ, Yuan J, Tran K, McKnight CJ, Hegele RA, Yao ZM. A novel nontrun-cating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia. J Biol Chem, 2003, 278: 13442– 13452.

[13] Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, Friedl W, Davignon J, McCarthy BJ. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholes-terolemia. J Lipid Res, 1990, 31: 1337–1349.

[14] Hobbs HH, Leitersdorf E, Leffert CC, Cryer DR, Brown MS, Goldstein JL. Evidence for a dominant gene that suppresses hypercholesterolemia in a family with defec-tive low density lipoprotein receptors. J Clin Invest, 1989, 84(2): 656–664.

[15] Johansen CT, Wang J, Lanktree MB, Cao HN, McIntyre AD, Ban MR, Martins RA, Kennedy BA, Hassell RG, Visser ME, Schwartz SM, Voight BF, Elosua R, Salomaa V, O'Donnell CJ, Dallinga-Thie GM, Anand SS, Yusuf S, Huff MW, Kathiresan S, Hegele RA. Excess of rare vari-ants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet, 2010, 42(8): 684–687.

[16] Teslovich TM, Musunuru K, Smith AV, Edmondson AC. Biological, clinical and population relevance of 95 loci for blood lipids. Nature, 2010, 466(7307): 707&n

Outlines

/